Keytruda's First FDA Approval
Keytruda (pembrolizumab) gained its initial FDA accelerated approval in September 2014 for unresectable or metastatic melanoma in patients whose tumors expressed PD-L1, based on data from the KEYNOTE-001 trial showing tumor shrinkage in 33% of those patients.[1][2]
What Made This Milestone Pivotal
This approval marked the first for any PD-1 inhibitor, proving the immunotherapy class could deliver durable responses—median progression-free survival hit 4.7 months versus months for prior standards like chemotherapy.[1] Patients with higher PD-L1 expression saw even better results, up to 45% response rates.[2]
How Keytruda's Mechanism Drove Early Wins
Keytruda blocks the PD-1 receptor on T-cells, unleashing them against melanoma cells expressing PD-L1. In KEYNOTE-001, this led to complete responses in 7% of PD-L1-positive cases, with some lasting years—unlike chemotherapy's short-lived effects.[1][3]
Trials Behind the Initial Data
KEYNOTE-001 enrolled 89 melanoma patients post-prior therapy. Objective response rate was 26% overall, jumping to 33% in PD-L1-positive subsets. Follow-up KEYNOTE-002 and -006 trials confirmed benefits, converting accelerated approval to full status by 2015.[1][2]
Expansions from Melanoma Roots
Post-melanoma, approvals quickly followed for non-small cell lung cancer (2015), head and neck squamous cell carcinoma (2016), and others. By 2024, Keytruda holds approvals in 35+ indications across 20 cancers.[4]
When Patents and Exclusivity End
Keytruda's core composition-of-matter patent (U.S. Patent No. 8,354,509) expires in 2028, with pediatric exclusivity pushing to 2029. Multiple method-of-use patents extend protection into the 2030s, but biosimilar challenges like Samsung Bioepis's FDA filing loom.[5]
[1]: FDA Approval Summary: Pembrolizumab (Keytruda)
[2]: KEYNOTE-001 Trial Results (NEJM)
[3]: Merck Keytruda Prescribing Information
[4]: Merck Oncology Pipeline
[5]: DrugPatentWatch: Keytruda Patents